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ABSTRACT.
Purpose: To ascertain resource use, costs and risk of workforce absence in non-
infectious uveitis cases versus matched controls.
Methods: In a retrospective claims analysis of employees in the United States,
prevalent (N = 705) and incident (N = 776) cases 18–64 years old with ≥2
diagnoses of non-infectious intermediate, posterior or panuveitis were matched
1:1 to controls without uveitis. Persistent prevalent cases (treated for ≥90 days,
N = 112) also were analysed. Outcomes were annual direct resource use and
costs associated with inpatient stays; emergency department, outpatient and
ophthalmologist/optometrist visits; and prescription drugs. Indirect resource use
and costs associated with work loss from disability and medically related
absenteeism also were compared. Multivariate regression assessed cost diﬀer-
ences between cases and controls.
Results: Cases had signiﬁcantly (p < 0.05) more medical resource use versus
controls including 0.4 versus 0.2 emergency visits and 16.5 versus 7.6 outpatient/
other visits. Cases used more prescription drugs (7.8 versus 4.1) and had more
disability days (10.3 versus 4.6), medically related absenteeism days (8.5 versus
3.8), and work loss days (18.7 versus 8.4) than controls (all p < 0.05). Total
direct ($12 940 versus $3730) and indirect ($3144 versus $1378) costs were
higher in cases than controls (all p < 0.05). Results for persistent cases suggested
greater utilization and associated cost and work loss burden. Compared with
controls, cases had signiﬁcantly greater risks of workforce absence, leave of
absence and long-term disability (all p < 0.05).
Conclusion: Non-infectious intermediate, posterior or panuveitis, particularly
persistent disease, is associated with substantial medical and work loss costs
suggesting an unmet need for more eﬀective treatments.
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Introduction
Uveitis is a broad term for inﬂamma-
tion inside the eye. Symptoms of uveitis
vary by anatomic location and include
redness, pain, photosensitivity and
blurred/reduced vision. Uveitis can be
infectious or non-infectious in origin,
with non-infectious disease predomi-
nating in the developed world (Mise-
rocchi et al. 2013). Non-infectious
uveitis may be idiopathic or associated
with systemic autoimmune diseases
(Rothova et al. 1996; Bodaghi et al.
2001; Chang & Wakeﬁeld 2002;
Nguyen et al. 2011; Barisani-Asen-
bauer et al. 2012; Chu et al. 2013;
Levin et al. 2014). Regardless of the
aetiology, persistent intra-ocular
inﬂammation can lead to structural
ocular complications and visual dis-
ability (Rothova et al. 1996; Durrani
et al. 2004a,b; Nguyen et al. 2011;
Barisani-Asenbauer et al. 2012; Chu
et al. 2013; Pan et al. 2014). The Stan-
dardization of Uveitis Nomenclature
(SUN) guidelines classify uveitis by
anatomic location as anterior, interme-
diate, posterior or panuveitis (Jabs
et al. 2005); hereafter, non-infectious
intermediate, posterior and panuveitis
will be referred to collectively as
NIIPPU. Compared with anterior dis-
ease, which is the most common non-
infectious form (Chang & Wakeﬁeld
2002; Gritz & Wong 2004; Acharya
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et al. 2013; Miserocchi et al. 2013),
NIIPPU is more often associated with
a poorer prognosis (Chang & Wake-
ﬁeld 2002; Barisani-Asenbauer et al.
2012).
Overall, uveitis is estimated to cause
approximately 5–15% of blindness in
the United States and Europe, making
it approximately the 5th or 6th leading
cause of preventable blindness (Nussen-
blatt1990; Rothova et al. 1996; Sut-
torp-Schulten & Rothova 1996; Durrani
et al. 2004a; Miserocchi et al. 2013).
Vision loss due to NIIPPU can nega-
tively aﬀect patients’ mental and phys-
ical health (Schiﬀman et al. 2001;
Murphy et al. 2005, 2007; Miserocchi
et al. 2010; Qian et al. 2012). Appr-
oved treatments for NIIPPU include
local and systemic corticosteroid ther-
apy and regional therapies such as
surgically placed corticosteroid impl-
ants, although conventional steroid-
sparing immunosuppressive agents
and biologics also are used in clinical
practice (Multicenter Uveitis Steroid
Treatment Trial Research Group et al.
2011; Gallego-Pinazo et al. 2013).
Disability associated with visual
impairment also can adversely aﬀect
patients’ ability to work and may lead
to absenteeism or early exit from the
workforce. Because NIIPPU has rela-
tively early onset and the incidence is
greatest in working age people (Sut-
torp-Schulten & Rothova 1996; Dur-
rani et al. 2004a; Acharya et al. 2013),
the costs to society in terms of medical
resource use and work disability could
be greater than those observed among
patients with blindness or visual
impairment associated with age-related
eye diseases. Nevertheless, current data
on the economic burden of non-infec-
tious uveitis are limited, aside from a
study by Chu et al. (2013) that
reported direct costs in a population
that included patients with anterior
disease. To our knowledge, the poten-
tial economic and resource burden
speciﬁcally for an NIIPPU population
has not been reported to date. To
augment the available literature, we
assessed direct (medical service and
prescription drug) and indirect (work
loss) resource use and costs for pri-
vately insured United States (US)
employees with NIIPPU and compared
them to matched controls without
uveitis; an analysis of persistent
NIIPPU cases also was conducted.
In addition, risks of workforce
absence associated with NIIPPU were
assessed.
Materials and Methods
Patient sample and data source
Two diﬀerent samples were extracted
from the OptumHealth Reporting and
Insights database from 1 January 1998
through 31 March 2012 (OptumHealth
website 2015). A cross-sectional sample
of prevalent NIIPPU cases (Fig. 1A)
was selected for analyses of utilization
and associated costs, and a longitudi-
nal sample of incident NIIPPU cases
(Fig. 1B) was selected for analyses of
workforce outcomes. Cases 18 to
64 years of age were identiﬁed using
International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁ-
cation (ICD-9-CM) codes for non-
infectious intermediate, posterior or
panuveitis [360.12 (panuveitis), 362.12
(exudative retinopathy), 362.18 (retinal
vasculitis), 363.0x (focal chorioretinitis
and focal retinochoroiditis), 363.10-13
and 363.15 (disseminated chorioretini-
tis and disseminated retinochoroiditis),
363.2x (other and unspeciﬁed forms of
chorioretinitis and retinochoroiditis,
including pars planitis) and 364.24
(Vogt-Koyanagi syndrome)]. Both pri-
mary and secondary NIIPPU diag-
noses were included, and ≥2 diagnoses
were required for conﬁrmation of the
condition. The selected codes were
modiﬁed from Reeves et al. (2006) to
exclude anterior and infectious uveitic
diagnoses. In the prevalent sample, a
subgroup of persistent NIIPPU cases
was deﬁned as those receiving
treatment for NIIPPU for ≥90 days
(corticosteroids, traditional immuno-
suppressants and/or biologic therapy)
(Jabs et al. 2005).
The OptumHealth database includes
16.4 million privately insured individu-
als from a diversity of industry sectors,
such as ﬁnancial services, manufactur-
ing, telecommunications, energy and
the food/beverage industry. Medical
and drug claims and eligibility data
are available for the primary policy-
holders and all beneﬁciaries. Addition-
ally, short- and long-term disability
claims for employees are available for
a subset of the companies. The data-
base is compliant with the Health
Insurance Portability and Accountabil-
ity Act. Ethics approval was not
required for this study because the data
analysed were de-identiﬁed records
from an administrative insurance data-
base.
Outcome measures
Available data included employees’
beneﬁt eligibility, medical and phar-
macy service claims, disability claims,
plan-speciﬁc length of waiting period
before short-term disability and salary
information. Direct resource outcomes
and associated costs included hospital-
izations, emergency department (ED)
visits, outpatient/other visits, ophthal-
mologist/optometrist visits and pre-
scription drug use. Indirect resource
outcomes included disability days asso-
ciated with extended absence from
work due to short- or long-term dis-
ability and medically related absen-
teeism days associated with medical
claims occurring during days of work.
Outcomes associated with leaving the
workforce were time to leave of
absence, short-term disability, long-
term disability and leaving for any of
these reasons plus early retirement.
Data analysis
NIIPPU cases were matched 1:1 on
sex, age, region and index date to
controls without uveitis. Baseline
demographic characteristics, ocular
and autoimmune comorbidities, and
Charlson Comorbidity Index (CCI)
were compared descriptively between
cases and controls using McNemar’s
tests for categorical variables and Wil-
coxon signed-rank tests for continuous
variables. Prevalent NIIPPU cases and
their matched controls who were eligi-
ble for the utilization and cost analyses
were required to have continuous eli-
gibility for ≥6 months before and
≥1 year after the index date (Fig. 1A).
The index date for cases was a ran-
domly selected NIIPPU diagnosis any
time during the baseline or follow-up
period. This approach allowed selec-
tion of a sample of NIIPPU patients
who were at a variety of points in their
disease course. Direct medical utiliza-
tion and costs were disaggregated by
place of service and included the fol-
lowing categories: inpatient, ED, and
outpatient/other; prescription drug uti-
lization and costs included all claims
for prescription drugs during the study
period. Direct healthcare costs were
calculated based on all payments to
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Cases With NIIPPU (N = 1122)
• ≥2 NIIPPU diagnoses 
• Employees from companies 
providing work loss data
Continuous Eligibility (N = 730)
• ≥6 months before index date 
(baseline period)
• ≥1 year after index date (study 
period)
Prevalent NIIPPU Cases and 
Controls (N = 705)
Cases aged 18 to 64 during baseline 
and study period matched 1:1 by sex, 
age, region, and index date to 
employed controls without an uveitis 
diagnosis 
Prevalent Sample
for Cost and Utilization Analyses
6-Month Baseline
Period 12-Month Study Period
Index Date: Randomly selected NIIPPU diagnosis for casesa
1 January
1998
31 March
2012
Persistent NIIPPU Subgroup (N = 112)
Cases were receiving treatment for 
NIIPPU for ≥90 days (corticosteroids, 
traditional immunosuppressants 
and/or biologic therapy)
Claimants With NIIPPU (N = 6399)
≥2 NIIPPU diagnoses  from 
Continuous Eligibility (N = 2781)
• ≥6 months of continuous eligibility 
before index date
• 18 to 64 years old
Incident NIIPPU Cases and Controls 
(N = 776)
• Employees from companies providing 
work loss data
• Cases matched 1:1 by sex, age, 
region, company, employment status 
on index date and index date to 
controls without an uveitis diagnosis 
Incident Sample
for Workforce Outcomes
6-Month Baseline
Period
Study Period: Cases/controls were 
followed from index date until loss of 
insurance eligibility or age 65.
1 January
1998
31 March
2012
Index Date: First NIIPPU diagnosis for casesb 
(A)
(B)
Fig. 1. Sample selection. (A) Prevalent sample for costs and utilization analyses. aIncludes NIIPPU cases at a variety of points in their disease (e.g.
recently diagnosed patients and patientswho haveNIIPPU for a longer period of time); it is possible thatNIIPPUpatients in the prevalent sample had an
NIIPPU diagnosis during the baseline period. Controls were assigned the index date of their matched NIIPPU case. (B) Incident Sample forWorkforce
Outcomes. bControls were assigned the index date of their matched NIIPPU case. NIIPPU, non-infectious intermediate, posterior or panuveitis.
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providers for medical services and
prescription drugs. Indirect resource
use and costs included both work loss
owing to disability and medically
related absenteeism. Days of disability
were computed by identifying the total
time covered by short- and long-term
disability claims. Medically related
absenteeism days were imputed based
on use of medical services during busi-
ness days (e.g. an oﬃce visit or a
hospital inpatient visit during Monday
through Friday), as well as the waiting
period in advance of the start of short-
term disability (e.g., ﬁve missed days of
work due to illness). The methodology
assumed that each hospitalization day
and ED visit accounted for a full day of
work loss, whereas each outpatient/
other visit accounted for half a day of
work loss. Disability costs were based
on actual employer disability pay-
ments, and medically related absen-
teeism costs were calculated based on
individual employee wage information
and days of medically related absen-
teeism. All costs were adjusted to 2012
US dollars. Direct and indirect
resource use and costs incurred during
the study period were compared
between the two cohorts using Wil-
coxon signed-rank or McNemar’s tests.
Multivariate regression assessed key
cost diﬀerences between cases and
controls, with adjustment for age, sex,
region, index year (full sample only)
and CCI.
Cases eligible for the risk of leaving
the workforce analyses were required
to be active employees in a company
providing work loss data on the date
of ﬁrst NIIPPU diagnosis; cases and
controls were followed from index
date until loss of insurance eligibility
or age 65 (Fig. 1B); the index date for
cases was the ﬁrst NIIPPU diagnosis
and controls were assigned the index
date of their matched case. Time-to-
event Kaplan–Meier analysis and log-
rank tests were used to compare risks
of leaving the workforce between cases
and controls. The time to each event
was calculated as the time from the
index date to the earliest event of that
type; cases and controls who did not
have the event after the index date
were censored at the last day of
follow-up (i.e. the end of eligibility
or when the participant turned 65 year
of age). Cox proportional hazards
regressions with adjustment for diﬀer-
ences in age, sex, region, CCI score,
presence of autoimmune diseases and
presence of human immunodeﬁciency
virus/acquired immunodeﬁciency syn-
drome (HIV/AIDS) were used to esti-
mate hazard ratios for NIIPPU cases
relative to controls during the entire
duration of follow-up, at 1 year and at
5 years.
Results
Baseline data
For the prevalent NIIPPU analysis (i.e.
resource use and cost analysis), the
mean age of the NIIPPU cases
(N = 705) and matched controls with-
out uveitis (N = 705) was 45.3 years,
and 63% were men. For all of the
selected baseline ocular and most of the
autoimmune comorbidities, signiﬁ-
cantly greater frequencies were
observed for the NIIPPU cohort
compared with matched controls
(Table S1). Retinal disorders (12% for
cases, 0.1% for controls), visual distur-
bances (11% for cases, 0.7% for con-
trols), glaucoma (7% for cases, 2% for
controls), and cataract (6% for cases,
0.4% for controls) were the most com-
mon ocular comorbidities among cases
(all p < 0.0001, McNemar’s test). Sar-
coidosis (3% for cases, 0.1% for con-
trols; p < 0.0001) and rheumatoid
arthritis (2% for cases, 0.4% for
controls; p < 0.0017) were the most
common baseline autoimmune comor-
bidities. All ocular and autoimmune
comorbidities, except for glaucoma,
were present in ≤1% of the matched
control population. Mean CCI scores
were signiﬁcantly greater in patients
with NIIPPU versus controls (0.9 ver-
sus 0.1; p < 0.0001, Wilcoxon signed-
rank test).
Mean age in the prevalent, persistent
NIIPPU subgroup (N = 112) was
47.8 years and 58% were men. Baseline
ocular complications, except for blind-
ness, were signiﬁcantly more common
in cases versus controls (all p ≤ 0.01;
Table S2). Retinal disorders (21% ver-
sus 0%) were the most common, fol-
lowed by glaucoma (15% versus 1%),
visual disturbances (13% versus 2%)
and cataract (12% versus 0%). Similar
to the full NIIPPU prevalent sample,
most the selected autoimmune comor-
bidities were signiﬁcantly more com-
mon among cases with persistent
NIIPPU versus controls. Mean CCI
was signiﬁcantly higher for persistent
cases (0.75) versus controls (0.21)
(p < 0.05).
For the incident NIIPPU analysis
(i.e., work loss analysis), mean age of
the NIIPPU cases (N = 776) and
matched sample (N = 776) was
44.7 years and 62% were men. All
ocular comorbidities were statistically
signiﬁcantly more common in cases
compared with the matched controls,
with retinal disorders (9% for cases,
0% for controls), visual disturbances
(10% for cases, 0.5% for controls) and
glaucoma (7% for cases, 1% for con-
trols) being the most common (all
p < 0.0001; Table S1). Across autoim-
mune comorbidities at baseline, inci-
dent NIIPPU cases had signiﬁcantly
(all p < 0.05) higher frequencies of any
selected autoimmune comorbidity
overall (10% cases, 2% controls), sys-
temic vasculitis (2% cases, 0% con-
trols), sarcoidosis (2% cases, 0%
controls), spondyloarthritis (1% cases,
0.1% controls) and multiple sclerosis
(1% cases, 0.1% controls) versus their
matched controls. Mean CCI scores for
incident NIIPPU patients were signif-
icantly greater than their matched
controls (0.8 versus 0.2; p < 0.0001).
Healthcare resource utilization
Annual direct healthcare resource uti-
lization was greater for patients with
NIIPPU than for their matched con-
trols without uveitis, both in terms of
the percentage of patients requiring
direct healthcare and/or prescription
drugs and the mean number of visits
and/or prescriptions (Fig. 2A). Specif-
ically, cases had higher incidences of
inpatient (12% versus 6%), ED (20%
versus 12%), and outpatient/other
(100% versus 79%) visits compared
with controls (all p < 0.0001, Wilcoxon
signed-rank test). In addition, 91% of
cases had claims for prescription drugs
compared with 68% of controls
(p < 0.0001). Cases had 16.5 outpatient
visits on average compared with 7.6
visits for controls, and cases were
treated with an average of 7.8 prescrip-
tion drugs compared with 4.1 prescrip-
tion drugs for controls (both
p < 0.0001); length of hospital stay
was not signiﬁcantly diﬀerent between
cases (6.7 days) and controls
(4.2 days). The pattern of results was
similar for the persistent NIIPPU sub-
group (Fig. 2B). Although statistical
comparisons between the full NIIPPU
e334
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sample and the persistent NIIPPU
subgroup were not performed, greater
percentages of NIIPPU cases in the
persistent population required direct
healthcare and/or prescription drugs
and more visits and prescriptions.
With respect to indirect healthcare
resource utilization in the full NIIPPU
sample (Fig. 3A), patients with
NIIPPU on average had a greater
number of disability days (10.3 ver-
sus 4.6; p < 0.05), medically related
absenteeism days (8.5 versus 3.8; p <
0.0001), and total days of work loss
(18.7 versus 8.4; p < 0.0001) compared
with their matched controls without
uveitis. In the persistent NIIPPU sub-
group, 15% of cases versus 6% of
controls had work disability (21.3 days
versus 7.5 days; p < 0.05); a total of
35.5 days of work were lost for
persistent NIIPPU cases versus 11.5
for the matched controls (p < 0.0001)
(Fig. 3B).
Healthcare costs
In the unadjusted cost analyses, total
direct costs were 3.5 times higher for
NIIPPU cases than for controls
(p < 0.0001; Fig. 4A); medical costs
($7790 versus $2645) were greater than
pharmacy costs ($5151 versus $1085).
Outpatient costs accounted for $5975
of the medical costs for NIIPPU cases
and $1997 for controls. Total indirect
costs were 2.3 times higher (p < 0.0001,
NIIPPU Cases          0.2a 0.4a 16.5a 3.6a 7.8a
Controls 0.1 0.2 7.6 0.3 4.1
Number of visits or drugs  
Persistent
NIIPPU Cases 0.3
b 0.6b 26.3a 6.6a 13.3a
Controls 0.1 0.1 9.4 0.5 4.5
Number of visits or drugs
(A)
(B)
Fig. 2. Direct Healthcare Resource Use. (A) Full NIIPPU sample. (B) Persistent NIIPPU subgroup. aP < 0.0001. bP < 0.05. NIIPPU, non-infectious
intermediate, posterior or panuveitis.
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multivariate regression; Fig. 4B), and
costs associated with medically related
absenteeism costs were greater than
disability costs (Fig. 4B). After adjust-
ment for potentially confounding base-
line characteristics, total direct
($11 424 versus $5090) and indirect
($3034 versus $1510) costs were signif-
icantly higher for NIIPPU cases than
for controls (both p < 0.0001; Fig-
ure S1).
For the persistent NIIPPU sub-
group, annual unadjusted mean direct
healthcare costs were 5.1 times greater
for cases versus controls ($26 279 ver-
sus $5181; p < 0.0001) (Fig. 4C). These
costs included medical costs (inpatient
[$3628 versus $586], outpatient
[$12 038 versus $3065], ophthalmol-
ogy/optometry [$3486 versus $830,
emergency [$267 versus $31]) and pre-
scription drug costs ($10 345 versus
$1499), all of which were signiﬁcantly
greater for cases versus controls (all
p < 0.05). Total indirect costs were 3.6
times greater for persistent NIIPPU
cases versus controls ($6624 versus
$1816; p < 0.0001) (Fig. 4D), with
medically related absenteeism costs
being 4.4 times greater for persis-
tent NIIPPU cases compared with
their matched controls. Adjusted
total direct costs were $35 739 for
persistent NIIPPU cases and $7670
for the matched controls (p < 0.0001);
adjusted total indirect costs were $6902
and $1612, respectively (p < 0.0001;
Figure S2).
Risk of workforce absence and disability
In unadjusted Kaplan–Meier analyses,
incident NIIPPU cases were at signif-
icantly greater risk of leaving the
workforce for any reason over the
course of follow-up compared with
their matched controls (p = 0.007,
log-rank test; Fig. 5). The 1-, 5- and
10-year probabilities of leaving the
workforce in NIIPPU cases were
11%, 31% and 44%, respectively,
compared with 8%, 23%, and 33%
for controls. Compared with controls,
cases also had signiﬁcantly greater risks
of leave of absence (p = 0.03; Fig-
ure S3) and long-term disability
(p = 0.01; Figure S4). Risk of short-
term disability was not statistically
signiﬁcant (Figure S5). In Cox regres-
sion models controlling for patient
demographics and clinical characteris-
tics, cases were signiﬁcantly more likely
than controls to leave the workforce
for any reason during the entire course
of follow-up (hazard ratio = 1.27;
p = 0.04); the 5-year risk was also
statistically signiﬁcant with a hazard
ratio of 1.29 (p = 0.03).
Discussion
The present study highlights the poten-
tially under-recognized health impact
of NIIPPU from the perspective of
direct medical resource use, work loss
outcomes and associated costs. With
an estimated prevalence of 58–115
cases per 100 000 persons in the United
States (Gritz & Wong 2004; Suhler
et al. 2008; Acharya et al. 2013),
NIIPPU is not particularly common;
however, sight-threatening complica-
tions, including macular oedema, glau-
coma, visual disturbances and
cataracts, are common in these patients
(Rothova et al. 1996; Durrani et al.
2004a,b; Levin et al. 2014; Tomkins-
Netzer et al. 2014; Jones 2015). The
majority of patients (63%) in this study
were men. In contrast, several epidemi-
ological studies of uveitis (all types)
have reported that the majority of
patients (52–57%) were women (Gritz
& Wong 2004; Acharya et al. 2013;
Bajwa et al. 2015). The reason for the
diﬀerence in demographics in our study
is directly related to selection of the
study sample. In order to evaluate the
risk of leaving the workforce among
patients with NIIPPU, the study sam-
ple was restricted to active employees
(i.e. primary policyholders) in compa-
nies providing work loss data in the
claims database. From overall labour
force demographics in the United
States, it is expected that selecting a
population with available workforce
data would result in a sample of
patients that is predominantly male.
Indeed, in an incident sample of uveitis
cases identiﬁed before restricting the
sample to active employees, the sample
was 45% male. Restricting the sample
to active employees with work loss data
NIIPPU Cases 
NIIPPU Cases 
10.3b 8.5a
b
18.7a
Controls 8.43.84.6
Number of days
Number of days
 
Controls
Persistent 21.3b 14.3a 35.5a
11.54.07.5
(A)
(B)
Fig. 3. Indirect Healthcare Assessment: Work disability. (A) Full NIIPPU sample. (B) Persistent
NIIPPU subgroup. aP < 0.0001. bP < 0.05. NIIPPU, non-infectious intermediate, posterior or
panuveitis.
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resulted in a smaller sample size that
was 63% male. It should be noted that
the matched controls in the work loss
and indirect cost analyses were also
required to be active employees in
companies providing work loss data.
In this study, patients with NIIPPU
had greater baseline prevalences of
ocular complications and systemic
comorbidities, including autoimmune
diseases and conditions such as diabetes
with complications, cerebrovascular
disease, rheumatic diseases and HIV/
AIDS than matched controls. Like-
wise, medical costs and prescription
drug costs during the 1-year study
period were 2.9 and 4.7 times higher,
respectively, for the NIIPPU cohort.
With medical costs 4.3 times higher
and prescription drug costs 6.9 times
higher for the persistent NIIPPU sub-
group versus matched controls, these
ﬁndings suggest even greater burden
for persistent disease.
Quantiﬁcation of the indirect cost
burden associated with workforce
absence in patients with NIIPPU is a
unique aspect of the present study.
NIIPPU often aﬀects patients during
their productive working years (Dur-
rani et al. 2004a; Acharya et al. 2013);
thus, disease-related work absenteeism
and disability is an important measure
of the potential economic consequences
of the disease. Greater durations of
medically related work absenteeism
among NIIPPU cases in translated to
associated indirect costs that were 2.5
times greater than those for controls
(4.4 times greater for persistent
NIIPPU), and patients with NIIPPU
also were more likely to be on short- or
long-term disability. These ﬁndings
underscore the importance of pursuing
optimal treatment initiatives to manage
the symptoms and comorbidities of this
sight-threatening disease, thereby
potentially increasing workforce par-
ticipation and reducing the socio-eco-
nomic burden of NIIPPU.
To our knowledge, the present study
is the ﬁrst to examine utilization, costs
and work loss outcomes speciﬁcally in
a population with NIIPPU. Chu et al.
(2013) recently reported costs and uti-
lization associated with non-infectious
uveitis in a privately insured popula-
tion in the United States. However, the
Chu et al. (2013) report diﬀered from
the present analysis in that it included
patients with anterior uveitis; patients
were required to be receiving treatment
with corticosteroids, immunosuppres-
sants or biologics without a control
group who did not have uveitis; and
work outcomes and indirect costs were
not reported. Although comparison of
results should be interpreted with cau-
tion for these reasons, Chu et al. (2013)
reported annual direct costs (in 2009
US dollars), including study drug costs,
of $13 728 for patients treated with
corticosteroids, $21 108 for patients
treated with immunosuppressants and
$32 268 for patients treated with bio-
logics. In comparison, annual utiliza-
tion costs for diseases such as diabetes
and hypertension have been estimated
to be $12 192 and $8676, respectively
(2009 US dollars); thus, the direct
economic burden of NIIPPU ($12 940
unadjusted, $11 424 adjusted) is at
least as great as that of these more
common conditions (Laliberte et al.
2009; Chu et al. 2013). Moreover, total
direct costs observed in the present
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Fig. 4. Costs for patients with NIIPPU versus controls. (A) Unadjusted direct costs: Full NIIPPU
sample. (B) Unadjusted indirect costs: full NIIPPU sample. (C) Unadjusted direct costs: persistent
NIIPPU subgroup. (D) Unadjusted indirect costs: persistent NIIPPU subgroup.aP < 0.0001.
bP < 0.05. NIIPPU, non-infectious intermediate, posterior or panuveitis; USD, US dollars.
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study for persistent NIIPPU ($26 279
unadjusted, $35 739 adjusted) exceed
those reported for other autoimmune
diseases such as Crohn’s disease
($18 022–$18 932), moderate-to-severe
ulcerative colitis ($23 085, adjusted)
and rheumatoid arthritis ($13 012,
adjusted) (Yu et al. 2008; Kawatkar
et al. 2012; Cohen et al. 2015).
The present study was subject to the
known limitations of retrospective
studies based on healthcare claims
data, including possible database
errors or omission of relevant claims.
Using claims data to identify patients
with NIIPPU may overestimate the
sample size. For example, one of the
ICD-9 codes (362.12 [exudative
retinopathy]) used to identify NIIPPU
cases in this study may include non-
inﬂammatory lesions with a range of
structural vascular pathology, such as
Coat’s disease. In addition, clinical
data were limited, and the diagnoses
of NIIPPU were not conﬁrmed by
ophthalmologic examinations. Altho-
ugh we controlled for several clinical
and demographic factors in the analy-
ses, claims data may not capture other
potentially relevant factors. Finally,
uveitis is frequently associated with
various immunological systemic dis-
eases (Barisani-Asenbauer et al. 2012;
Pan et al. 2014). It is possible that
some of the workforce loss seen in this
study is related to underlying systemic
conditions. On the other hand, it is
also possible that uveitis itself increases
the likelihood of work loss in patients
with idiopathic disease. Because sys-
temic comorbidities are an integrated
part of the burden of uveitis, this
study focused on results associated
with the overall burden of uveitis
without separating idiopathic from
systemic autoimmune disease-related
uveitis. Future research may be use-
ful to further assess the diﬀerential
burden between these two types of
uveitis.
Strengths of claims data analyses
include that they allow for identiﬁca-
tion of relatively large samples of cases
that can be matched to controls that
represent a cross-sectional sample with
health conditions and comorbidities
other than the disease under study. In
addition, claims data provide good
representation of the insured working
US population; however, results may
not be generalizable to uninsured and
elderly populations. Claims database
also include patients treated at both
primary care and specialty centres,
which reduces referral bias.
In conclusion, NIIPPU was associ-
ated with substantial direct healthcare
costs, both medical and pharmacy,
compared with matched controls with-
out uveitis. NIIPPU cases also had
greater indirect costs associated with
increased work disability and absen-
teeism. Persistent NIIPPU was associ-
ated with greater baseline ocular and
autoimmune comorbidities, resource
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Fig. 5. Survival Analyses for Risk of Leaving the Workforce, All-Cause. aKaplan–Meier analyses encompassed the entire follow-up period; however,
only the ﬁrst 10 years are displayed. bHRs and 95% CIs were estimated from adjusted Cox regression analyses, controlling for age, sex, region, CCI,
autoimmune disease and HIV/AIDS; ratios represent the hazard for NIIPPU cases relative to controls. cAll-cause was deﬁned as events of leave of
absence, short-term disability, long-term disability or early retirement. AIDS, acquired immunodeﬁciency syndrome; CCI, Charlson Comorbidity
Index; CI, conﬁdence interval; HIV, human immunodeﬁciency virus; HR, hazard ratio; NIIPPU, non-infectious intermediate, posterior or panuveitis.
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use and cost burdens. Together, these
ﬁndings underscore the unmet need for
additional therapies, for currently cor-
ticosteroids are the only approved
treatment.
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